ArticlePubMed 90
In the LIVE trial, liraglutide treatment resulted in no change in left ventricular systolic function, whereas liraglutide related to an increase in heart rate and more serious cardiac adverse events among chronic heart failure patients with and without type 2 diabetes [45]
In 2023, Eli Lilly entered the market with Zepbound (tirzepatide), boasting over 20% weight loss at 72 weeks and a slightly lower price
however these adverse reactions were tolerable and mostly temporary
Rabobank: Its way too early to draw conclusions However, Nick Fereday, senior analyst, consumer foods at Rabobank, says we should be careful about making sweeping predictions about the future of the food industry based on preliminary survey data from a relatively small number of GLP-1 drug users
M., Du, Y., Lou, J., Gurbuz, S., & Coskun, T